Switching between anti-calcitonin gene-related peptide monoclonal antibodies: A comparison of monthly and quarterly dosing - Ihara, Keiko; Ohtani, Seiya; Watanabe, Narumi; Takahashi, Nobuyuki; Miyazaki, Naoki; Takemura, Ryo; Hori, Satoko; Nakahara, Jin; Takizawa, Tsubasa (Journal of the neurological sciences, 2023)
Keywords: Antibodies, Monoclonal - adverse effects; Calcitonin Gene-Related Peptide; CGRP; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Fremanezumab; Galcanezumab; Hospitals, University; Humans; Injection Site Reaction; Migraine; Migraine Disorders; Neurology; Real-world; Retrospective Studies; Switch; Treatment Outcome; RR; Fremanezumab; FH; MMD; Migraine; CI; Real-world; MOH; MHD; EM; Galcanezumab; CM; NRS; Switch; AMD; CGRP; CGRPmAb; BMI; anti-calcitonin gene-related peptide monoclonal antibody; monthly migraine days; monthly headache days; numerical rating scale; International Classification of Headache Disorders, 3rd edition; chronic migraine; ICHD-3; responder rate; body mass index; monthly acute medication days; calcitonin gene-related peptide; medication overuse headache; episodic migraine; family history; confidence interval